To investigate the clinical efficacy of Xinmailong on heart failure in coronary heart disease and on the levels of hs-C-reactive protein(hs-CRP)and N-terminal B-type natriuretic peptide(NT-proBNP).

84 elderly patients diagnosed with heart failure in coronary heart disease were enrolled in this study at our hospital from October 2014 to October 2015.All patients were randomly divided into the control group with conventional treatment(n=42)and observation group with conventional plus Xinmailong treatment(n=42). The Lee’s heart failure score, cardiac function grade, quality of life score and the changes of plasma hs-CRP and NT-proBNP after one week of therapy were compared between the two groups before versus after treatment.The adverse reactions were observed during the treatment.

The clinical efficacy rate of heart failure after treatment was significantly higher in the observation group(83.3%, 35 cases)than in control group(54.7%, 23 cases)(χ²=8.016, P=0.033). The clinical efficacy of heart function after treatment was significantly higher in the observation group(80.9%, 34 cases)than in the control group(59.5%, 25 cases)(χ²=6.219, P=0.019). After treatment, the quality of life score was significantly lower in observation group(15.89±3.39)than in the control group(23.80±5.66)(t=7.266, P=0.026). The plasma levels of NT-proBNP and hs-CRP were significantly lower after than before treatment in NT-proBNP〔(1 136.6±236.8)ng/L and (2 266.9±260.9)ng/L〕, and in hs-CRP〔(3.06±0.26)mg/L and (3.56±0.29)mg/L〕(t=6.608、5.106, P=0.019、0.009). There were no serious adverse reactions in both groups during the treatment.

Xinmailong can not only improve safely and effectively the quality of life of patients, but also block the atherosclerosis of the inflammatory response.

Heart failure; Natriuretic peptide, brain; C-reactive protein